Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 31,428,572 shares of its common stock. The shares of common stock are being sold to the public at a price of $17.50 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $550.0 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 4,714,285 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on July 15, 2026, subject to the satisfaction of customary closing conditions. Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering. The securities described above are being offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) on July 13, 2026 and automatically became effective upon filing. A preliminary prospectus supplement relating to this offering has be...